NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

6970.50 32.50 (0.47%)

New 52W High in past week

38,427 NSE+BSE Volume

NSE 09 Jul, 2025 9:37 AM (IST)

185,044.9

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Dividend

Divi's Laboratories Ltd. has an upcoming dividend of ₹30.00 per share due on 25 Jul 2025 See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

31 Jan 2018

6970.50

0.47%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 6% YoY to | 1038 crore (I-direct estimate: | 957 crore) driven by growth across segments EBITDA margins declined 724 bps YoY to 31.4% (I-direct estimate: 36%), impacted mainly by lower gross margins (60.7% in Q3FY18 vs. 64.1% in Q3FY17), higher remediation cost & forex loss of | 16 crore in Q3FY18 vs. gain of | 0.7 crore in Q3FY17. Subsequently, EBITDA declined 14% YoY to | 326 crore (I-direct estimates of | 345 crore)...

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

29 Jan 2018

6970.50

0.47%

Divi's Labs (3QFY18): Normalcy returns. Maintain NEUTRAL

Neutral: Divi's Laboratories Ltd.

HDFC Securities

Maintain NEUTRAL rating, with a revised TP of Rs 1,100 (22x Dec-19E). 3QFY18 was Divis Labs (DIVI) first quarter post the lifting of the import alert on Unit II, and the recovery began well. The top-line came in at Rs 10.4bn, (in-line with estimates), up ~8%/17% YoY/QoQ. Strong growth in the CMS (+10% YoY) and nutraceuticals businesses (+23% YoY) boosted the top-line.

Divi's Laboratories Ltd. has gained 56.14% in the last 1 Year

Divi's Laboratories Ltd.

29 Jan 2018

6970.50

0.47%

Divi's Lab: Revenues outperform but margins below expectatio... (Jan 29, 2018)

Sell: Divi's Laboratories Ltd.

Target

Karvy

Divis Labs Net revenues increased by 6.2% YoY to Rs 10.4 bn, higher thanour estimates of Rs 9.8 bn for the quarter. The Operating margins were at31.4% in Q3 FY18 (lower than our estimate of 32.9%) as against 38.7% inQ3FY17 on account of lower gross margin and higher other expenses.

Divi's Laboratories Ltd. has gained 56.14% in the last 1 Year

Divi's Laboratories Ltd.

28 Jan 2018

6970.50

0.47%

Divi's Laboratories: Revenue improves sequentially; margin impacted by forex loss

Neutral: Divi's Laboratories Ltd.

Motilal Oswal

DIVI reported healthy revenue growth of 8% YoY and 17% QoQ in 3QFY18 to INR10.4b (v/s our estimate of INR9.9b). It has reported revenue growth after three quarters due to regulatory issues at its Unit-II, which have now been resolved. EBITDA declined ~14% YoY but grew ~18% QoQ to INR3.3b. Margin declined 790bp YoY (flat QoQ) to 31.4%. PAT declined 16.3% (grew 9%QoQ) to INR2.2b, ~3% below our estimate. DIVI incurred forex loss of INR160m, adjusting for which margin would have been ~33%. It incurred remediation cost of INR140m, which is expected to decline to INR50m-60m in 4QFY18. Remediation cost will not be incurred from FY19. We expect EBITDA margin to improve by ~400bp to ~36%, with no remediation expenses from next fiscal.

Divi's Laboratories .. has an average target of 5900.88 from 8 brokers.

Divi's Laboratories Ltd.

07 Nov 2017

6970.50

0.47%

Company Update:Divis Lab.

Buy: Divi's Laboratories Ltd.

Target

Axis Direct

While Divis reported 11% YoY decline in Q2 revenue (19% YoY decline in Q1), it exhibited 8% QoQ growth as most plant protocols and procedures (leading to manufacturing disruption) suggested in remediation plan were completed in Q1.

Divi's Laboratories .. has an average target of 5900.88 from 8 brokers.

Divi's Laboratories Ltd.

03 Nov 2017

6970.50

0.47%

Divi's Labs (Update): Lift off. Maintain NEUTRAL

Neutral: Divi's Laboratories Ltd.

Target

HDFC Securities

On the back of the regulatory relief, we have increased our EPS estimates for FY18E/FY19E/FY20E by ~9%/14%/14%. We also upgrade the earnings multiple from 16x previously, to 22x, in-line with DIVI's historical 1-year forward multiple. However, with the recent run-up in the stock price, there is limited up-side. Maintain NEUTRAL, with a revised TP of Rs 1,100 (22x Sep-19E). The US FDA has lifted the 66-40 import alert on Divis Labs (DIVI) crucial Unit 2 facility in Vizag. DIVI has managed this within 8 months, a record for Indian players. It has traditionally taken peers 2 to 3 years to resolve issues of a similar scale at US FDA-approved facilities, hence this news is extremely positive, and speaks volumes of managements ability and execution.

Divi's Laboratories Ltd. has gained 29.39% in the last 3 Months

Divi's Laboratories Ltd.

03 Nov 2017

6970.50

0.47%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 12% YoY to | 890 crore (I-direct estimate: | 959 crore), mainly due to loss of sales and delays of export shipments of...

Divi's Laboratories Ltd. has gained 56.14% in the last 1 Year

Divi's Laboratories Ltd.

02 Nov 2017

6970.50

0.47%

Divi's Laboratories: US FDA clears Unit-2; positives already priced in

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi's Laboratories (DIVI) announced that the US FDA will lift the import alert under clause 66-32 at the Vishakhapatnam-based Unit-2 facility. Exposure to the US market from Unit-2 stands at ~22% of total sales (pre-import alert). This has been one of the fastest resolutions post receipt of the import alert in Mar17. Import alert under clause 99-32 was lifted in Jul-17: In July-17, the US FDA lifted the import alert under clause 99-32 on the company's Unit-2 at Visakhapatnam. The FDA had issued an import alert under clauses 99-32 and 66-40 in March 2017 and a warning letter in May 2017 for the Vishakhapatnam...

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

01 Nov 2017

6970.50

0.47%

Divi's Labs (2QFY18): Regulatory hurdles persist. Maintain NEUTRAL

Neutral: Divi's Laboratories Ltd.

HDFC Securities

We maintain NEUTRAL rating on the stock, with a revised TP of Rs 700 (16x Sep-19E). Divis Labs (DIVI) reported a muted performance in 2QFY18. Revenue for the quarter was Rs 8.9bn, (~4% below estimates), a decline of ~11% YoY, with the impact of the import alert continuing to be felt. Supply protocols for a plant under an import alert have resulted in slower output for DIVI. EBITDA came in at ~Rs 2.8bn, a margin of 31.1% (in-line with estimates). However, contrary to our expectations, there continued to be remediation costs during this quarter (~Rs 170mn), adjusted for which, the EBITDA margin would be ~33%, a ~190bps beat. PAT was ~Rs 2bn (down ~8% YoY), ~5% below estimates.

Divi's Laboratories Ltd. has gained 56.14% in the last 1 Year

Divi's Laboratories Ltd.

01 Nov 2017

6970.50

0.47%

Divi's Laboratories: Regulatory issues impact revenues

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

~INR170m related to the import alert at Unit II. PAT of INR2.1b (down ~32% YoY) was ~4% below our estimate. Remediation over at Unit-2: DIVI has already completed remediation for observations highlighted by the USFDA in a re-inspection. Management too has met the USFDA in late Oct-17. The company believes that till the import alert resolution does not happen, the sales run-rate will remain at 2Q levels. Capex plan: DIVI spent ~INR4.5b as capital work in progress till end-FY17 to expand capacity at Unit-1 and 2. The company plans to spend ~INR3.65b in...

Divi's Laboratories Ltd. has gained 29.39% in the last 3 Months

Is Divi's Laboratories Ltd. worth buying?

750 Votes:

Buy 78.0%

Sell 15.07%

Hold 6.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf